抗HPV-16E_6单抗对宫颈癌靶向性的研究

Localizing ability of monoclonal antibody against HPV-16 E_6 protein to target cervical cancer

目的 :评价抗HPV - 16E6 单克隆抗体靶向定位于宫颈癌组织的能力。方法 :用99Tcm 标记抗HPV - 16E6 单克隆抗体 (抗HPV - 16E6 +McAb ,实验组 )和正常鼠免疫球蛋白 (nMIgG ,对照组 )后 ,分别进行荷HPV - 16E6 +U14宫颈癌小鼠放射免疫显像 ,并比较放免结果。结果 :99Tcm 抗HPV - 16E6 McAb及99Tcm-nMIgG标记率分别为 91.97%和92 .4 9% ;标记前后抗体的免疫活性未改变 ;2 4h显像可见实验组肿瘤部位放射性浓集 ,图象清晰 ,肿瘤和非肿瘤组织放射性比值 (T/NT)明显高于对照组 (P <0 .0 5 )。结论 :抗HPV -16E6 单克隆抗体具有特异性定位于宫颈癌组织的能力 。

Objective:To evaluate the localizing ability of HPV-16 E 6McAb to target the foci of cervical cancer.Methods:HPV-16 E 6McAb and normal murine IgG(nMIgG) were labeled with the technetium-99m( 99 Tc m).The immunoconjugates were intravenously injected into 615 strain mice bearing HPV-16 E 6 +U14 cervical carcinoma respectively and then radioimmunoimaging was performed in two groups of mice.Results:91.97% radiolabeling yield was obtained in 99 Tc m -labeled HPV-16 E 6McAb while 92.49% in 99 Tc m-labeled nMIgG . Immunoreactivity of HPV-16 E 6McAb did not change after radiolabeling.The radioimaging showed that 99 Tc m-labeled HPV-16 E 6McAb concentrated in the tumor tissue after 24 hours from injection while radioactivity did not concentrated in the tumor tissue in the control group.Good immunoreactivity of HPV-1 6E 6McAb retained with higher ratio of tumor to normal tissue radioactivity (T/NT) than that of nMIgG and the difference was significant(P<0.05). Conclusions:Monoclonal antibody against HPV-16 E 6 protein can specifically localize in the tumor tissue of mice bearing HPV-16 E 6 +U14 cervical carcinoma.HPV-16 E 6McAb may be effectively used for radioimmunoimaging diagnosis and targeted therapy to metastic and recurrent foci of cervix carcinoma.